tetano
Editor, Senior Moderator
Antiviral Res. 2016 Aug 1. pii: S0166-3542(16)30245-5. doi: 10.1016/j.antiviral.2016.07.021. [Epub ahead of print]
[h=1]Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design.[/h] Liu WC[SUP]1[/SUP], Liu YY[SUP]2[/SUP], Chen TH[SUP]3[/SUP], Liu CC[SUP]4[/SUP], Jan JT[SUP]5[/SUP], Wu SC[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Virus-like particle (VLP) technology is an attractive platform for seasonal and pandemic influenza vaccine development. We previously showed that influenza VLPs can be modified using M2 fusion with molecular adjuvants such as Salmonella typhimurium flagellin (FliC) to enhance VLP immunogenicity. For this study, three types of chimeric VLPs were incorporated with FliC, granulocyte-macrophage colony-stimulating factor (GM-CSF), or both GM-CSF and FliC (GM-CSF/FliC) to enhance anti-influenza immunogenicity. Our results indicate that immunizations with the chimeric FliC VLPs and GM-CSF/FliC H5N1 VLPs elicited more potent and broadly neutralizing antibodies and neuraminidase-inhibiting antibodies in sera, and induced higher numbers of hemagglutinin-specific antibody-secreting cells and germinal center B cell subsets in splenoctyes. Immunization with the chimeric GM-CSF H5N1 VLPs induced stronger Th1 and Th2 cellular responses. The chimeric GM-CSF/FliC H5N1 VLP constructs were further obtained to include H7 or H1H7 bi- or tri-subtype. It is our hope that these findings provide useful information for developing multi-subtype influenza vaccines.
Copyright ? 2016. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] Influenza; Multi-subtype vaccine; Virus-like particle
PMID: 27491439 DOI: 10.1016/j.antiviral.2016.07.021
[PubMed - as supplied by publisher]
[h=1]Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design.[/h] Liu WC[SUP]1[/SUP], Liu YY[SUP]2[/SUP], Chen TH[SUP]3[/SUP], Liu CC[SUP]4[/SUP], Jan JT[SUP]5[/SUP], Wu SC[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Virus-like particle (VLP) technology is an attractive platform for seasonal and pandemic influenza vaccine development. We previously showed that influenza VLPs can be modified using M2 fusion with molecular adjuvants such as Salmonella typhimurium flagellin (FliC) to enhance VLP immunogenicity. For this study, three types of chimeric VLPs were incorporated with FliC, granulocyte-macrophage colony-stimulating factor (GM-CSF), or both GM-CSF and FliC (GM-CSF/FliC) to enhance anti-influenza immunogenicity. Our results indicate that immunizations with the chimeric FliC VLPs and GM-CSF/FliC H5N1 VLPs elicited more potent and broadly neutralizing antibodies and neuraminidase-inhibiting antibodies in sera, and induced higher numbers of hemagglutinin-specific antibody-secreting cells and germinal center B cell subsets in splenoctyes. Immunization with the chimeric GM-CSF H5N1 VLPs induced stronger Th1 and Th2 cellular responses. The chimeric GM-CSF/FliC H5N1 VLP constructs were further obtained to include H7 or H1H7 bi- or tri-subtype. It is our hope that these findings provide useful information for developing multi-subtype influenza vaccines.
Copyright ? 2016. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] Influenza; Multi-subtype vaccine; Virus-like particle
PMID: 27491439 DOI: 10.1016/j.antiviral.2016.07.021
[PubMed - as supplied by publisher]